Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: Immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination

Vaccine

Volumn 29, Issue 40, 2011, Pages 6888-6893

  Lagler, Heimo ^a   Wenisch, Judith M ^a   Tobudic, Selma ^a   Gualdoni, Guido A ^a   Rödler, Susanne ^a   Rasoul Rockenschaub, Susanne ^a   Jaksch, Peter ^a   Redlberger Fritz, Monika ^b   Popow Kraupp, Theresia ^b   Burgmann, Heinz ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Immunogenicity; Influenza A (H1N1); Solid organ transplantation; Tolerability; Vaccine

Indexed keywords

CYCLOSPORIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS;

ADULT; AGED; ARTICLE; AUSTRIA; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG TOLERABILITY; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SEROCONVERSION; VACCINATION; VERO CELL; VIRION;

ADULT; ANIMALS; ANTIBODIES, VIRAL; AUSTRIA; CERCOPITHECUS AETHIOPS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNE TOLERANCE; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; SEROLOGIC TESTS; TRANSPLANTATION IMMUNOLOGY; VACCINATION; VERO CELLS; VIRION;

EID: 80052304465     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.050     Document Type: Article

References (29)

1. Smud A., Nagel C.B., Madsen E., Rial Mdel C., Barcan L.A., Gomez A.A., et al. Pandemic influenza A/H1N1 virus infection in solid organ transplant recipients: a multicenter study. Transplantation 2010, 90:1458-1462.
2. Evison J., Farese S., Seitz M., Uehlinger D.E., Furrer H., Muhlemann K. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis 2009, 48:1402-1412.
3. Cavdar C., Sayan M., Sifil A., Artuk C., Yilmaz N., Bahar H., et al. The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients. Scand J Urol Nephrol 2003, 37:71-76.
4. Kunisaki K.M., Janoff E.N. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009, 9:493-504.
5. Kumar D., Michaels M.G., Morris M.I., Green M., Avery R.K., Liu C., et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010, 10:521-526.
6. Kumar D., Morris M.I., Kotton C.N., Fischer S.A., Michaels M.G., Allen U., et al. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant 2010, 10:18-25.
7. Barrett P.N., Berezuk G., Fritsch S., Aichinger G., Hart M.K., El-Amin W., et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011, 377:751-759.
8. Coudeville L., Bailleux F., Riche B., Megas F., Andre P., Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a Bayesian random-effects model. BMC Med Res Methodol 2010, 10:18.
9. Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009, 360:2605-2615.
10. Girard M.P., Tam J.S., Assossou O.M., Kieny M.P. The 2009 A (H1N1) influenza virus pandemic: a review. Vaccine 2010, 28:4895-4902.
11. Committee for Human Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines. London 1997. Available from: [accessed 10.06.11]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf.
12. Monto A.S., Ansaldi F., Aspinall R., McElhaney J.E., Montano L.F., Nichol K.L., et al. Influenza control in the 21st century: optimizing protection of older adults. Vaccine 2009, 27:5043-5053.
13. European Medicines Agency. Assessment Report for Celvapan. Common Name: Pandemic influenza vaccine (H1N1) (whole virion, Vero cell derived, inactivated) A/California/07/2009 (H1N1)v. London 01 October 2009.Available from: [accessed 10.06.11]. http://www.ema.europa.eu/docs/en_GB/document_%20library/EPAR_-_Assessment_Report_-_Variation/human/000982/WC500022669.pdf.
14. Crowe B.A., Bruhl P., Gerencer M., Schwendinger M.G., Pilz A., Kistner O., et al. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. Vaccine 2010, 29:166-173.
15. Johansen K., Nicoll A., Ciancio B.C., Kramarz P. Pandemic influenza A(H1N1) 2009 vaccines in the European Union. Euro Surveill 2009, 14:19361.
16. Virologische Arbeitsmethoden, Band II (Serologie) 1977, 207-291. Gustav Fischer Verlag, Stuttgart. A. Mayr, B.A. Bachmann, B. Bibrack, G. Wittmann (Eds.).
17. Meyer S., Adam M., Schweiger B., Ilchmann C., Eulenburg C., Sattinger E., et al. Antibody response after a single dose of an AS03-adjuvanted split-virion influenza A (H1N1) vaccine in heart transplant recipients. Transplantation 2011, 91:1031-1035.
18. Manuel O., Pascual M., Hoschler K., Giulieri S., Alves D., Ellefsen K., et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011, 52:248-256.
19. Nicholson K.G., Abrams K.R., Batham S., Clark T.W., Hoschler K., Lim W.S., et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011, 11:91-101.
20. Waddington C.S., Walker W.T., Oeser C., Reiner A., John T., Wilkins S., et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010, 340:c2649.
21. Miller E., Hoschler K., Hardelid P., Stanford E., Andrews N., Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010, 375:1100-1108.
22. Stepanova L., Naykhin A., Kolmskog C., Jonson G., Barantceva I., Bichurina M., et al. The humoral response to live and inactivated influenza vaccines administered alone and in combination to young adults and elderly. J Clin Virol 2002, 24:193-201.
23. Remarque E.J. Influenza vaccination in elderly people. Exp Gerontol 1999, 34:445-452.
24. Dikow R., Eckerle I., Ksoll-Rudek D., Hampel H., Schwenger V., Zeier M., et al. Immunogenicity and efficacy in hemodialysis patients of an AS03(A)-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial. Am J Kidney Dis 2011, 57:716-723.
25. El-Madhun A.S., Cox R.J., Haaheim L.R. The effect of age and natural priming on the IgG and IgA subclass responses after parenteral influenza vaccination. J Infect Dis 1999, 180:1356-1360.
26. Birdwell K.A., Ikizler M.R., Sannella E.C., Wang L., Byrne D.W., Ikizler T.A., et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. Am J Kidney Dis 2009, 54:112-121.
27. de Jong J.C., Palache A.M., Beyer W.E., Rimmelzwaan G.F., Boon A.C., Osterhaus A.D. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 2003, 115:63-73.
28. Scharpe J., Evenepoel P., Maes B., Bammens B., Claes K., Osterhaus A.D., et al. Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant 2008, 8:332-337.
29. Salles M.J., Sens Y.A., Boas L.S., Machado C.M. Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugs. Clin Transplant 2010, 24:E17-E23.